Eczema can occur all over the body, but certain types (dyshidrotic, atopic dermatitis, neurodermatitis, and stasis dermatitis) are commonly found on the feet. Learn more about eczema on your feet, its ...

The hidden triggers behind eczema flare-ups Understanding what sparks eczema episodes has become crucial for effective management. While researchers haven’t pinpointed a single cause, evidence ...

By Breakingviews The brain-trust behind the benchmark S&P 500 Index (SPX) made a bold move: it did nothing. For the first time in more than three years, no new companies were added to the tracker ...

The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.

NEWCASTLE UNITED’S hopes of finally landing Marc Guehi have suffered a major blow with Liverpool now established as firm favourites to sign the Crystal Palace centre-half. Newcastle made Guehi ...

Dhar noted that when you google the words “diet” and “eczema,” about half of the results come from self-proclaimed “experts,” 30% from educational websites, and 20% from promotional sites.

For instance, a 2017 study in 169 people with eczema found that around 40% tried a gluten-free diet to reduce their symptoms. Of them, 51.4% reported improvements after cutting out gluten.

Hand eczema is common in winter and can cause deep cracks, peeling, and blisters on the tops of your hands, palms, or fingers, according to Jeffrey Benabio, MD, a dermatologist with Kaiser ...

Video: What to Know About Treatment of Atopic Dermatitis Based on the 2024 AAD Guidelines —Megan Rogge, MD, associate professor of dermatology at UT Health in Houston, shares her opinion on the ...

Galderma has shared positive two-year data for its monoclonal antibody Nemluvio (nemolizumab) in moderate-to-severe atopic dermatitis. The ARCADIA long-term extension (LTE) study has been evaluating ...

Primary Source JAMA Dermatology Source Reference: Lin T-L, et al "Psoriasis risk in patients with atopic dermatitis treated with dupilumab" JAMA Dermatol 2025; DOI: 10.1001/jamadermatol.2025.1578.

The Phase 1b trial is designed to evaluate the safety, tolerability, pharmacokinetics, target engagement, and early signs of efficacy of ENV-294 in patients with moderate to severe atopic dermatitis.